CDNACaredx Inc
$29.40
$1.56
(5.66%)
Closed $29.11
$0.29
(1.00%)
After Hours
EarningsAug 5
Mkt Cap$1.42B
Vol699,851.00
CareDx Completes Naveris Acquisition and Expands Oncology Reach
CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.
Zacks
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms...
Business Wire
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, highvalue healthcare solutions for transplant patients and caregivers, today announced the closing of the previously...
Business Wire
CareDx's CEO Sells 17K Shares
Key PointsThe CEO sold 17,683 shares for a transaction value of approximately ~$425,000 at a weighted average of around $24.03 per share on June 15...
Nasdaq News: Markets
CareDx Reaches Analyst Target Price
In recent trading, shares of CareDx Inc (Symbol: CDNA) have crossed above the average analyst 12-month target price of $25.80, changing hands for $26.18/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation...
Nasdaq News: Markets
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, highvalue healthcare solutions for transplant patients and caregivers, today announced its participation at the...
Business Wire
CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, highvalue healthcare solutions for transplant patients and caregivers, today announced the publication of a new...
Business Wire
CareDx to Participate in Upcoming Investor Conferences
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, highvalue healthcare solutions for transplant patients and caregivers, today announced the company will participate in...
Business Wire
CareDx Announces Dismissal of 2021 Qui Tam Suit
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...
Business Wire
<
1
2
...
>